Title

Complete Revascularization by Percutaneous Coronary Intervention for Patients With ST-Segment-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease: An Updated Meta-Analysis of Randomized Trials.

Journal

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 9(12)

Authors

Ahmad, Yousif
Howard, James
Arnold, Ahran
et al.

Publication Date

2020-06-16

DOI

10.1161/JAHA.119.015263

Peer reviewed

Journal of the American Heart Association

SYSTEMATIC REVIEW AND META-ANALYSIS

Complete Revascularization by Percutaneous Coronary Intervention for Patients With ST-Segment–Elevation Myocardial Infarction and Multivessel Coronary Artery Disease: An Updated Meta-Analysis of Randomized Trials

Yousif Ahmad, MRCP; James P. Howard, MRCP; Ahran Arnold, MRCP; Megha Prasad, MD; Henry Seligman, MRCP; Christopher M. Cook, MRCP; Takayuki Warisawa, MD; Matthew Shun-Shun, PhD; Ziad Ali, DPhil, MD; Manish A. Parikh, MD; Rasha Al-Lamee, PhD, MD; Sayan Sen, PhD, MD; Darrel Francis, MD; Jeffrey W. Moses, MD; Martin B. Leon, MD; Gregg W. Stone, MD; Dimitri Karmpaliotis, PhD, MD

BACKGROUND: For patients with ST-segment–elevation myocardial infarction (STEMI) and multivessel coronary artery disease, the optimal treatment of the non-infarct-related artery has been controversial. This up-to-date meta-analysis focusing on individual clinical end points was performed to further evaluate the benefit of complete revascularization with percutaneous coronary intervention for patients with STEMI and multivessel coronary artery disease.

METHODS AND RESULTS: We systematically identified all randomized trials comparing complete revascularization with percutaneous coronary intervention to culprit-only revascularization for multivessel disease in STEMI and performed a random-effects meta-analysis. The primary efficacy end point was cardiovascular death analyzed on an intention-to-treat basis. Secondary end points included all-cause mortality, myocardial infarction, and unplanned revascularization. Ten studies (7542 patients) were included: 3664 patients were randomized to complete revascularization and 3878 to culprit-only revascularization. Across all patients, complete revascularization was superior to culprit-only revascularization for reduction in the risk of cardiovascular death (relative risk [RR], 0.68; 95% CI, 0.47–0.98; P=0.037; I^2=21.8%) and reduction in the risk of myocardial infarction (RR, 0.65; 95% CI, 0.54–0.79; P<0.0001; I^2=0.0%). Complete revascularization also significantly reduced the risk of unplanned revascularization (RR, 0.37; 95% CI, 0.28–0.51; P<0.0001; I^2=64.7%). The difference in all-cause mortality with percutaneous coronary intervention was not statistically significant (RR, 0.85; 95% CI, 0.69–1.04; P=0.108; I^2=0.0%).

CONCLUSIONS: For patients with STEMI and multivessel disease, complete revascularization with percutaneous coronary intervention significantly improves hard clinical outcomes including cardiovascular death and myocardial infarction. These data have implications for clinical practice guidelines regarding recommendations for complete revascularization following STEMI.

Key Words: percutaneous coronary intervention ■ revascularization ■ ST-segment–elevation myocardial infarction

Primary percutaneous coronary intervention (PCI) of the infarct-related artery reduces mortality and myocardial infarction (MI) in patients with ST-segment–elevation MI (STEMI).[1] STEMI patients commonly have multivessel coronary artery disease (CAD)[1,2] and the presence of multivessel disease confers a worse prognosis.[3]

Correspondence to: Yousif Ahmad, MRCP, Columbia University Medical Center/New York-Presbyterian Hospital, New York, NY. E-mail: ya2431@cumc.columbia.edu

Supplementary Materials for this article are available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.015263

For Sources of Funding and Disclosures, see page 14.

JAHA is available at: www.ahajournals.org/journal/jaha

CLINICAL PERSPECTIVE

What Is New?

- Primary percutaneous coronary intervention for patients with ST-segment–elevation myocardial infarction reduces mortality and myocardial infarction.
- For patients with multivessel coronary artery disease, the optimal treatment of the non-infarct-related artery has been controversial.
- For patients with ST-segment–elevation myocardial infarction and multivessel disease, complete revascularization with percutaneous coronary intervention significantly improves hard clinical outcomes including cardiovascular death and myocardial infarction.

What Are the Clinical Implications?

- Clinical guidelines may need to be updated in light of these findings.

Nonstandard Abbreviations and Acronyms

CAD	coronary artery disease
FFR	fractional flow reserve
PCI	percutaneous coronary intervention
PPCI	primary percutaneous coronary intervention
STEMI	ST-segment–elevation myocardial infarction

The treatment of non-infarct related arteries in STEMI patients has been controversial, and previously was considered to be a class III indication[4,5] outside of the setting of cardiogenic shock, largely on the basis of observational studies.[6] More recently, randomized controlled trials (RCTs) in the field have suggested that complete revascularization with PCI is safe for these patients and may be beneficial. Guidelines now permit PCI to the non-infarct-related artery for STEMI patients but are still somewhat conservative.[7,8]

The RCTs in the field to date and meta-analyses of them have primarily demonstrated reductions in composite end points (typically major adverse cardiac events, which are defined variably across trials).

With the publication of the largest RCT to date in this field (the COMPLETE [Complete versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease after Early PCI for STEMI] trial[9]) and longer-term follow-up available from another trial,[10] we sought to perform an up-to-date meta-analysis focusing on individual clinical end points to further evaluate the benefit of complete revascularization with PCI for patients with STEMI and multivessel CAD.

METHODS

The data that support the findings of this study are available from the corresponding author on reasonable request.

We carried out a meta-analysis of RCTs that evaluated complete revascularization with PCI for patients with STEMI and multivessel disease. The analysis was conducted in accordance with the published PRISMA guidance[11] and was prospectively registered at the PROSPERO (international prospective register of systematic reviews) (CRD42020149243).

Search Strategy

We performed a systematic search of the Medline, Cochrane Central Register of Controlled Trials, and Embase databases from September 2019 to January 2020 for all studies of complete revascularization in STEMI. Our search strings included (*STEMI* or *ST-segment myocardial infarction*) AND *multivessel*; and *percutaneous coronary intervention*, respectively. We also hand-searched the bibliographies of relevant selected studies, reviews, and meta-analyses to identify further eligible studies. Abstracts were reviewed for suitability and articles accordingly retrieved. Two independent reviewers performed the search and literature screening (Y.A. and A.A.), with disputes resolved by consensus following discussion with a third author (J.H.).

Inclusion and Exclusion Criteria

We considered all randomized studies of complete revascularization in STEMI. Studies were eligible if they reported clinical outcome data following randomization to complete or culprit-only revascularization. Observational and unpublished studies were not considered.

End Points

The primary efficacy end point was cardiovascular death, and the primary safety end point was risk of major bleeding. We considered MI, all-cause mortality, unplanned revascularization, and contrast-induced nephropathy as secondary end points. All analyses were at the latest available follow-up.

Data Extraction and Analysis

Two authors (Y.A. and A.A.) independently abstracted the data from included trials, verified by a third author (J.H.). Included studies were assessed using the Cochrane Risk of Bias tool.[12] Tests for publication bias would be performed only in the event of ≥10 trials being included for analysis, and a Funnel plot would be used.[13]



Figure 1. Search strategy and source of included studies.
CTO indicates chronic total occlusion.

We analyzed efficacy on an intention-to-treat basis. The primary outcome measure was the relative risk (RR) of cardiovascular death. Random-effects meta-analyses were performed using the restricted maximum likelihood estimator. Additional analyses were performed using fixed effects. All outcomes were assessed as RRs.

As a secondary analysis, we analyzed cardiovascular death, MI, all-cause mortality, and unplanned revascularization as hazard ratios when the trials reported these data. We extracted the hazard ratios with their associated 95% CIs and *P* values. A random-effects meta-analysis was performed of the natural logarithm of the hazard ratios and their associated standard errors using the restricted maximum likelihood estimator. The standard error was calculated by dividing the difference between the natural logarithms of the upper and lower 95% CIs by 2 times the appropriate normal score (1.96). Where the lower 95% CI level approached zero, the standard error was calculated using only the difference between the natural logarithm of the upper 95% CI level and the natural logarithm of the point estimate.

We used the I^2 statistic to assess heterogeneity.[14] Low or mild heterogeneity was defined as 0% to 30%; moderate heterogeneity was defined as 31% to 60%; and >60% was defined as substantial heterogeneity. Mean values are expressed as mean±SD unless otherwise stated. Statistical significance was set at $P<0.05$. The statistical programming environment R[15] with the *metafor* package[16] was used for all statistical analysis.

Subgroups

We specified the timing of complete revascularization (immediate or staged) as a subgroup

Table 1. Characteristics of Included Studies

Author	Study Acronym	Year	Region	N	Mean Age*	Follow-Up, mo†	Entry Criteria	Complete Revascularization	Culprit-Only Revascularization	Non-Culprit-Vessel Criteria	Primary Efficacy Outcomes	Safety Outcomes
Mehta et al[9]	COMPLETE	2019	31 countries across North America, Europe, Asia and Africa‡	4041	61.6 (±10.7)	35.8 (IQR, 27.6–44.3)	STEMI with culprit primary PCI and at least 1 nonculprit angiographically significant lesion and patient able to be randomized within 72 h of culprit-lesion PCI	Staged PCI of all nonculprit lesions either during admission or after discharge, ≤45 d from randomization	No further revascularization unless protocol criteria for crossover met	At least 70% stenosis or 50%–69% stenosis with FFR ≤0.80	Composite of cardiovascular death, new MI. Composite of cardiovascular death, new MI, ischemia-driven revascularization	Major bleeding, contrast-associated acute kidney injury
Smits et al[17]	Compare-Acute	2017	24 centers in Europe and Asia	885	62 (±10)	36	STEMI with culprit primary PCI and at least 1 nonculprit artery amenable to PCI	FFR measurement: if ≤0.80, nonculprit revascularization during index admission preferably within 72 h	FFR measurement without revascularization but planned revascularization within 45 d could occur (without knowledge of FFR)	>50% stenosis in major artery or branch vessel >2 mm diameter, FFR ≤0.80	Composite of all-cause mortality, nonfatal MI, any revascularization, cerebrovascular events	Net adverse clinical events, death from any cause or MI, any bleeding, hospitalization for heart failure, unstable angina r chest pain, revascularization, stent thrombosis
Hamza et a[18]	NA	2016	Not stated (authors' centers are Egypt and USA)	100	56.4 (±11.5)	6	STEMI in patients with diabetes mellitus undergoing primary PCI with nonculprit stenosis	PCI to all nonangiographically culprit lesions either at time of primary PCI or within 72 h	Not specifically stated	80% stenosis of vessel	Composite of all-cause mortality, recurrent MI, ischemia-driven revascularization	Major bleeding, contrast-induced nephropathy
Zhang et a[19]	NA	2015	Not stated (authors' centers are in China)	428	NA	NA	STEMI in patients undergoing primary PCI with nonculprit stenoses	Staged PCI to nonculprit vessels 7–10 d after primary PCI	PCI to nonculprit lesions if evidence of ischemia (symptoms, ECG changes, nuclear study)	75%–90% stenosis	All cause mortality, cardiovascular death, MI	Hospitalizations
Engstrøm et al[20]	DANAMI-3-PRIMULTI	2015	Denmark	627	63 (34–92)	27 (12–24)	STEMI in patients undergoing primary PCI with >50% stenosis in nonculprit artery	Staged PCI to nonculprit artery if FFR ≤0.80, 2 d after initial PCI	No further revascularization planned	>50% stenosis in vessel >2 mm diameter, FFR ≤0.80	Composite of all-cause mortality, reinfarction, or ischemia-driven (subjective or objective) revascularization	Periprocedural MI, bleeding requiring transfusion or surgery, contrast-induced nephropathy, stroke
Gerschlick et al[10,21]	CvLPRIT	2015	UK	296	64.6 (±11.2)	66 (0–87)	STEMI in patients undergoing primary PCI with nonculprit artery with angiographically significant stenosis	PCI to nonculprit artery during primary PCI procedure	No further revascularization planned	>70% diameter stenosis in 1 plane or >50% in 2 planes in major/branch vessel >2 mm diameter	Composite of all-cause mortality, recurrent MI, heart failure, revascularization	Cardiovascular death, stroke, major bleeding, contrast-induced nephropathy

(*Continued*)

Table 1. Continued

Author	Study Acronym	Year	Region	N	Mean Age*	Follow-Up, mo†	Entry Criteria	Complete Revascularization	Culprit-Only Revascularization	Non-Culprit-Vessel Criteria	Primary Efficacy Outcomes	Safety Outcomes
Wald et al[22]	PRAMI	2013	UK	465	62 (32–92)	23	STEMI in patients undergoing primary PCI with nonculprit artery with angiographically significant stenosis	PCI to nonculprit artery during primary PCI procedure	PCI to residual stenoses only if refractory angina and objective ischemia test positive	>50% stenosis in nonculprit artery	Composite of cardiovascular death, nonfatal MI, refractory angina	Noncardiovascular death, repeated revascularisation were secondary outcomes
Dambrink et al[23]	n/a	2010§	Netherlands	121	62 (±10)	36	STEMI in patients undergoing primary PCI with at least 2 angiographically significant stenoses in different vessels (or branch plus vessel)	PCI to nonculprit artery before discharge if FFR positive	Ischemia-guided additional revascularization if symptomatic (exercise testing, dobutamine stress echocardiography, or myocardial scintigraphy)	>50% stenosis in >2.5 mm vessel if FFR ≤0.75	Ejection fraction	MACE
Politi et al[24]	NA	2010	All authors' centers are in Italy	263	65.2±12.2	30 (±17)	STEMI in patients undergoing primary PCI with at least 2 angiographically significant stenoses in different vessels	Two arms: (1) staged PCI to nonculprit artery, (2) PCI to nonculprit artery during primary PCI procedure	No further revascularization planned	>70% stenosis	Composite of cardiac or noncardiac death, in-hospital death, reinfarction, rehospitalization for acute coronary syndrome and repeated coronary revascularization	Contrast-induced nephropathy
Di Mario et al[25]	HELP AMI	2004	Authors' centers are in UK and Italy	69	65.3 (±7.4)	12	STEMI with angiographically severe stenosis in at least 2 major vessels	Nonculprit PCI performed during primary PCI procedure	Nonculprit PCI according to physician's discretion based on symptoms and ischemia testing	Major vessel (% not stated) but balloon angioplasty allowed in vessel <2.5 mm if at least 1 main vessel also stented	Repeat revascularization	MACE

Compare Acute indicates Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction; COMPLETE, Complete versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease after Early PCI for STEMI; CvLPRIT, Complete Versus Lesion-Only Primary PCI trial; DANAMI 3 PRIMULTI, Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease; FFR, fractional flow reserve; HELP-AMI, Hepacoat for Culprit or Multivessel Stenting for Acute Myocardial Infarction; IQR, interquartile range; MACE, major adverse cardiac events; MI, myocardial infarction; NA, not available; PCI, primary catheter intervention; PRAMI, Preventive Angioplasty in Acute Myocardial Infarction; and STEMI, ST-segment–elevation myocardial infarction.

*Mean age, where stated, in years (±SD) or median age (interquartile range) except for PRAMI, where mean (range) is provided; value for complete revascularization group provided where values differ between groups.

†Mean follow-up duration, where stated, in months (±SD where provided) except for COMPLETE and CvLPRIT, where median and IQR are provided, and Compare-Acute, Hamza et al[18], and HELP AMI, where follow-up duration was specified; value for complete revascularization group provided where values differ between groups.

‡Majority of patients recruited in Canada and United Kingdom (2293, 56%).

Table 2. Risk of Bias of Included Studies

Author	Study Acronym	Year	Random Sequence Generation	Allocation Concealment	Blinding of Participants and Personnel	Blinding of Outcome Assessment	Incomplete Outcome Data	Selective Reporting	Other Bias
Mehta et al[9]	COMPLETE	2019	Low risk Computer-generated system	Low risk Computer-generated system	Unclear Not specified	Low risk Events adjudicated by independent committee	Low risk Low drop-out rate	Low risk Pre-specified outcomes reported	Low risk Partly industry-funded but these parties not involved in study design or management
Smits et al[17]	Compare-Acute	2017	Low risk Opaque envelope system	Low risk Opaque envelope system	Unclear Not specified	Low risk Events adjudicated by independent committee	Low risk Low dropout rate	Low risk Prespecified outcomes reported	Low risk Partly industry funded but these parties not involved in study design or management
Hamza et al[18]	NA	2016	Unclear Not specified	Unclear Not specified	Unclear Not specified	Unclear Not specified	Low risk Low dropout rate	High risk Not preregistered and protocol not published	Unclear Source of funding not stated
Zhang et al[19]	NA	2015	Unclear Not specified	Unclear Not specified	Unclear Not specified	Unclear Not specified	Unclear Not specified	High risk Not preregistered and protocol not published	Unclear Source of funding not stated
Engstrøm et al[20]	DANAMI-3-PRIMULTI	2015	Low risk Centralized web-based system	Unclear Not specified	High risk Open-label study	Low risk Outcomes adjudicated by independent events committee	Low risk Low dropout rates	Low risk Prespecified outcomes reported	Low risk Funded by independent body
Gerschlick et al[10,21]	CvLPRIT	2015	Low risk Interactive voice-response program	Low risk Automated telephone randomisation	High risk Open label	Low risk Outcome adjudication by blinded clinicians	High risk Low dropout rates in both groups but low event rate	Low risk Prespecified outcomes reported	Low risk Funded by independent body
Wald et al[22]	PRAMI	2013	Low risk Computer generated	Unclear Not specified	High risk Open label for participants	Low risk Blinded adjudication	High risk Low dropout rates in both groups but low event rate	Low risk Prespecified outcomes reported	High risk Early termination (significant between groups difference in primary outcome)

(*Continued*)

Table 2. Continued

Author	Study Acronym	Year	Random Sequence Generation	Allocation Concealment	Blinding of Participants and Personnel	Blinding of Outcome Assessment	Incomplete Outcome Data	Selective Reporting	Other Bias
Dambrink et al[23]	n/a	2010	Low risk Computer-based randomization	Unclear Not specified	Unclear Not specified	Unclear Not specified for primary outcomes	Low risk Low rates of dropout	High risk Not preregistered and protocol not published	High risk Early termination (due to slow enrollment), source of funding not stated
Politi et al[24]	n/a	2010	Low risk Computerized randomization	Unclear Not specified	Unclear Not specified	Unclear Not specified	Unclear Not specified	High risk Not preregistered and protocol not published	Unclear Source of funding not stated
Di Mario et al[25]	HELP AMI	2009	Unclear Not specified	Unclear Not specified	Unclear Not specified	Unclear Not specified	Unclear Not specified	High risk Not preregistered and protocol not published	Unclear Source of funding not stated

analysis. Interactions between subgroups were assessed with metaregression using a mixed-effects model.

RESULTS

Ten studies[9,17–25] enrolling 7542 patients met the inclusion criteria (Figure 1). Of those, 3664 patients were randomized to complete revascularization and 3878 to culprit-only revascularization, with a weighted mean follow-up of 31.4 months.

Across all studies, the mean age was 62 years. The full characteristics of included studies including follow-up duration, inclusion criteria, and end points are shown in Table 1, and important differences are highlighted below.

There was some variation in study design between the included trials. The timing of non–culprit vessel PCI in the complete revascularization arms of the trials varied between nonculprit PCI during the primary PCI procedure, staged PCI before discharge from the index admission, staged PCI after discharge, or combinations of these strategies. PRAMI (Preventive Angioplasty in Acute Myocardial Infarction), CvPLRIT (Complete Versus Lesion-Only Primary PCI) trial and HELP-AMI (Hepacoat for Culprit or Multivessel Stenting for Acute Myocardial Infarction) all included an arm in which nonculprit PCI was specified to occur during the index primary PCI procedure, whereas COMPLETE allowed staged PCI after discharge up to 45 days after the index procedure. The location, degree, and index vessel diameter thresholds for coronary stenoses to achieve angiographic significance also varied between included studies: PRAMI was the least restrictive, permitting 50% visual stenosis to be an appropriate nonculprit lesion, whereas Hamza et al[18] required 80% stenosis. Compare Acute (Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction), DANAMI-3-PRIMULTI (complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease), and Dambrink et al[23] all required fractional flow reserve (FFR) assessment of the stenosis. Definitions of clinical end points used in each trial are shown in Table S1.

Trial quality was assessed using the Cochrane risk-of-bias tool and is shown in Table 2. Given the inherent difficulty in sham-blinding nonculprit PCI, none of the trials adequately blinded the patient or the operator to treatment allocation. However, most outcomes assessed, such as all-cause mortality, cardiovascular death, and nonfatal MI, are relatively bias-resistant in this regard, with the exception of unplanned revascularization. There was no evidence of publication bias as assessed by the funnel plot (P=0.669; see Figure S1).

A summary of stent types used in the included trials is shown in Data S1.



Figure 2. Effect of complete revascularization on cardiovascular death.
Compare Acute indicates Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction; COMPLETE, Complete versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease after Early PCI for STEMI; CvLPRIT, Complete Versus Lesion-Only Primary PCI trial; DANAMI 3 PRIMULTI, Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment–elevation myocardial infarction and multivessel disease; PRAMI, Preventive Angioplasty in Acute Myocardial Infarction.

Efficacy of Complete Versus Culprit-Only Revascularization

Cardiovascular Death

Complete revascularization with PCI resulted in a significant reduction in the risk of cardiovascular death (RR, 0.68; 95% CI, 0.47–0.98; *P*=0.037; Figure 2). There was low heterogeneity (I^2=21.8%).

Myocardial Infarction

Complete revascularization with PCI resulted in a significant reduction in the risk of MI (RR, 0.65; 95% CI, 0.54–0.79; *P*<0.0001; Figure 3). There was no heterogeneity (I^2=0.0%). This result was unchanged by restricting the inclusion to patients with spontaneous MI (RR, 0.58; 95% CI, 0.46–0.73; *P*<0.001; I^2=0.0%; Figure S2).

All-Cause Mortality

The effect of complete revascularization with PCI on all-cause mortality was an RR of 0.85 (95% CI, 0.69–1.04; *P*=0.108; Figure 4). There was no heterogeneity (I^2=0.0%).

Unplanned Revascularization

Complete revascularization with PCI resulted in a significant reduction in the risk of unplanned revascularization (RR, 0.37; 95% CI, 0.28–0.51; *P*<0.0001; Figure 5). There was significant heterogeneity (I^2=64.7%).

Safety of Complete Revascularization

The effect of complete revascularization with PCI on major bleeding was an RR of 1.12 (95% CI, 0.78–1.62; *P*=0.540; Figure 6). There was minimal heterogeneity (I^2=3.9%). The effect of complete revascularization with PCI on contrast-induced nephropathy was an RR of 1.42 (95% CI, 0.88–2.30; *P*=0.152; I^2=0.0%; Figure S3).

Impact of Timing of Complete Revascularization

Six trials[16,17,20,21,23,24] reported outcomes for all-cause mortality, MI, and unplanned revascularization in patients who underwent immediate complete revascularization. Four trials[16,20,21,23] reported outcomes for cardiovascular death in patients who underwent immediate revascularization. Five trials[9,18,19,22,23] reported outcomes for all-cause mortality, MI, and unplanned revascularization in patients who underwent staged complete revascularization. Four trials[9,18,19,23] reported outcomes for cardiovascular death in patients who underwent staged revascularization. Staged complete revascularization was performed within a wide temporal interval, from during the index admission up to 45 days after the initial PCI procedure.



Figure 3. Effect of complete revascularization on myocardial infarction.
Compare Acute, Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction; COMPLETE, Complete versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease after Early PCI for STEMI; CvLPRIT, Complete Versus Lesion-Only Primary PCI trial; DANAMI 3 PRIMULTI, Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment–elevation myocardial infarction and multivessel disease; HELP-AMI, Hepacoat for Culprit or Multivessel Stenting for Acute Myocardial Infarction; PRAMI, Preventive Angioplasty in Acute Myocardial Infarction.

Subgroup analysis did not demonstrate evidence of a significant interaction between the timing of complete revascularization and reduction in cardiovascular death (*P*=0.15; Figure 7).

Subgroup analysis did not demonstrate evidence of a significant interaction between the timing of complete revascularization and the reduction of unplanned revascularization (*P*=0.86). Subgroup analysis also did not demonstrate evidence of a significant interaction between the timing of complete revascularization and the reduction of MI, but the *P* value was borderline (0.05). These plots are shown in Figures S4 and S5.

Impact of Revascularization Guided by FFR

Three trials[16,19,22] reported outcomes for all-cause mortality, MI, and unplanned revascularization in patients who underwent complete revascularization guided by FFR. Two trials[16,19] reported outcomes for cardiovascular death in patients who underwent complete revascularization guided by FFR. Seven trials[9,17,18,20,21,23,24] reported outcomes for all-cause mortality, MI, and unplanned revascularization in patients who underwent complete revascularization guided by angiography. Five trials[9,18,20,21,23] reported outcomes for cardiovascular death in patients who underwent complete revascularization guided by angiography. The COMPLETE trial was regarded as using an angiographic-guided approach because only a very small proportion (0.8%) of patients had treatment guided by FFR.

Subgroup analysis did not demonstrate evidence of a significant interaction between the FFR versus angiography-guided revascularization for any of the end points. Forest plots for each of these end points are shown in Figures S6 through S9.

Hazard Ratio Analysis

We performed a secondary analysis looking at the efficacy end points using hazard ratios, which is more appropriate for time-to-event data but is limited by the reporting of the individual trials. Five trials reported hazard ratios for cardiovascular death, all-cause mortality, MI, and unplanned revascularization. The results are consistent with the main RR analysis for the end points of MI and unplanned revascularization, and the effect sizes were very similar for cardiovascular death, although they failed to reach statistical significance in light of the smaller sample size. These plots are shown in Figures S10 through S13.

Fixed-Effects Analyses

We performed an additional analysis looking at fixed-effects analyses for all our main end points, the results



Figure 4. Effect of complete revascularization on all-cause mortality.
Compare Acute, Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction; COMPLETE, Complete versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease after Early PCI for STEMI; CvLPRIT, Complete Versus Lesion-Only Primary PCI trial; DANAMI 3 PRIMULTI, Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment–elevation myocardial infarction and multivessel disease; HELP-AMI, Hepacoat for Culprit or Multivessel Stenting for Acute Myocardial Infarction; PRAMI, Preventive Angioplasty in Acute Myocardial Infarction.

of which are consistent with our random-effects analyses, and the plots are shown in Figures S14 through S18.

Sensitivity Analyses

We performed a sensitivity analysis including only trials assessed as being at low risk of bias. The results are consistent with the main analysis. These plots (for cardiovascular death, MI, all-cause mortality, and unplanned revascularization) are available in Figures S19 through S22.

We also performed sensitivity analyses excluding trials with low use of drug-eluting stents (defined as <50% of the total trial population). These results are shown in Figures S23 through S27 and are consistent with the main analysis.

We performed a further *jackknife* or *leave one out* sensitivity analysis, excluding each individual included trial in turn. These plots (for cardiovascular death, MI, all-cause mortality, and unplanned revascularization) are available in Figures S28 through S64.

DISCUSSION

In this study we have shown (1) that for patients with STEMI and multivessel disease, the risk of cardiovascular death is reduced by complete revascularization (RR, 0.68; 95% CI, 0.47–0.98; *P*=0.037), and (2) that this reduction in cardiovascular death is may partially be driven by a reduction in MI, which has a similar pooled point estimate (RR, 0.65; 95% CI, 0.54–0.79; *P*<0.0001).

Superiority of Complete Revascularization to Culprit-Only Revascularization

The individual trials included in this meta-analysis have shown reduction in unplanned revascularization with a strategy of complete revascularization after STEMI. This finding is intuitive because all patients in the culprit-only arm, by eligibility criteria, had angiographically severe stenoses amenable to PCI, and cardiologists were not blinded to their allocation to the culprit-only arms. Some trials also demonstrated a reduction in MI, including the most recent COMPLETE trial,[9] which is the largest trial in the field to date. In the current era of contemporary pharmacotherapy and continued advances in stent technology and implantation techniques, hard event rates are low. This makes it difficult for any individual trial in the field of STEMI to show benefits in terms of mortality end points. Consequently, we must turn to meta-analysis to synthesize all available trial data.

By doing so, we are now able to observe, for the first time, a statistically significant benefit to complete revascularization in STEMI for the end point of cardiovascular



Figure 5. Effect of complete revascularization on unplanned revascularization.
Compare Acute, Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction; COMPLETE, Complete versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease after Early PCI for STEMI; CvLPRIT, Complete Versus Lesion-Only Primary PCI trial; DANAMI 3 PRIMULTI, Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment–elevation myocardial infarction and multivessel disease; HELP-AMI, Hepacoat for Culprit or Multivessel Stenting for Acute Myocardial Infarction; PRAMI, Preventive Angioplasty in Acute Myocardial Infarction.

death. The mechanism of this reduction in cardiovascular death might be driven by a reduction in MI, particularly as the effect size is similar for these 2 end points. Other possible mechanisms include reduction in ischemia-driven arrhythmias and heart failure, but no definitive causation can be determined from this analysis.

Our analysis did not demonstrate a statistically significant benefit for complete revascularization with PCI in terms of all-cause mortality (RR, 0.84; 95% CI, 0.69–1.04; *P*=0.113). This may be due to insufficient power, and future trials in the field may help to identify a benefit in terms of all-cause mortality, which is the most bias-resistant end point. There was no heterogeneity for this outcome, and in fact heterogeneity was also low or absent for MI and cardiac death. This implies consistent findings across the included studies and strengthens the conclusions of our analysis.

Implications for Clinical Practice

It is important that the results of these trials, and the current analysis, are not conflated with the treatment of stable angina, for which PCI should still generally be offered with the goal of alleviating symptoms.[25] Moreover, this analysis serves to further illustrate the marked differences between patients who have had STEMI and those who have stable angina or stable CAD. The 2 entities are pathophysiologically and biologically distinct and therefore require distinct therapeutic strategies.

Clinicians treating patients with STEMI and multivessel disease have, broadly, 3 different management strategies to choose from: stenting the infarcted artery only and leaving all residual disease to medical therapy (culprit-only PCI), treating all appropriate stenoses at the time of STEMI (immediate complete revascularization), and treating the infarct-related artery at the time of STEMI and tackling the residual disease during another procedure (staged complete revascularization).

We sought to investigate whether the timing of complete revascularization had an impact on clinical outcomes. Subgroup analyses did not demonstrate evidence of a significant interaction between the timing of intervention in our analysis; that is, there was a consistent treatment effect for complete revascularization versus infarct-related artery PCI, regardless of the timing when complete revascularization was achieved. Furthermore, the largest RCT in the field to date (COMPLETE) had no immediate PCI arm (patients underwent PCI to achieve complete revascularization in a staged procedure, either during the hospital admission or as an outpatient within 45 days). A further analysis from the COMPLETE trial, initially presented at Transcatheter Therapeutics 2019 and published



Figure 6. Effect of complete revascularization on major bleeding.
Compare Acute, Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction; COMPLETE, Complete versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease after Early PCI for STEMI; CvLPRIT, Complete Versus Lesion-Only Primary PCI trial; DANAMI 3 PRIMULTI, Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment–elevation myocardial infarction and multivessel disease; PRAMI, Preventive Angioplasty in Acute Myocardial Infarction.

subsequently,[26] did not demonstrate a difference between complete revascularization during the index admission (median, 1 day), or after discharge from the hospital (median, 23 days), with a *P* value for interaction of 0.62 for the outcome of cardiac death or new MI.

It is unlikely that a group in that trial undergoing immediate complete revascularization with PCI would have had better outcomes than a group undergoing staged PCI a median of 1 day after the index procedure. We suggest that achieving complete revascularization, rather than timing of it, is the most important determination of clinical outcomes for these patients. This is also supported by the fact we did not observe a significant interaction whether complete revascularization was guided by FFR or angiography.

Our analysis has not suggested any safety concerns regarding complete revascularization. There was no significant increase in major bleeding or acute kidney injury. These data are reassuring, but treating clinicians must weigh the benefits of complete revascularization (reduction in cardiac death, myocardial infarction, and future revascularization) against potential risks (both short and long term) on an individual case-by-case basis. Our analysis demonstrates a reduction in MI with complete revascularization. The ISCHEMIA trial presentation has suggested that in stable CAD, invasive therapy leads to greater procedural MI but less spontaneous MI. This cannot necessarily be extrapolated to the patient population studied in this analysis, but future trials may wish to separately report periprocedural and spontaneous MI in all patients to permit a more nuanced interpretation of the results and to better advise patients on potential risks and benefits.

Implications for Clinical Practice Guidelines

PCI of the non-infarct-related artery was previously given a class III recommendation in guideline documents, but as further RCTs emerged, guideline recommendations were updated.

European guidelines from 2017[7] now give a IIa recommendation (level of evidence, A) and state that "routine revascularization of non-infarct-related artery lesions should be considered in STEMI patients with multivessel disease before hospital discharge." American College of Cardiology and American Heart Association guidelines from 2015[5] give a IIb recommendation (level of evidence, B-R) and state that "PCI of a non-infarct artery may be considered in selected patients with STEMI and multivessel disease who are hemodynamically stable, either at the time of primary PCI or as a planned procedure."

On the basis of the totality of the randomized trial data and this analysis, guidelines should be updated to give a class I recommendation for complete revascularization in appropriate STEMI patients.



Figure 7. Effect of timing of complete revascularization on cardiovascular (CV) death.
Compare Acute, Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction; COMPLETE, Complete versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease after Early PCI for STEMI; CvLPRIT, Complete Versus Lesion-Only Primary PCI trial; DANAMI 3 PRIMULTI, Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment–elevation myocardial infarction and multivessel disease; PRAMI, Preventive Angioplasty in Acute Myocardial Infarction.

Prior Work in the Field

Our meta-analysis differs from previous analyses in several ways. First, and most obviously, it includes the COMPLETE trial, which is by some margin the largest study in the field; we have also included long-term follow-up from the CvLPRIT trial. Second, we used individual end points rather any composite measures such as major adverse cardiac events. The use of composite measures for such an analysis is problematic. If the hazard ratios are synthesized for major adverse cardiac events or the primary composite end point, as it is defined in each individual trial, this will be hampered by the varying definitions seen in each trial. Essentially, disparate data will be meta-analyzed. If events from individual clinical end points counting and combined to assess major adverse cardiac events or another composite, then there is a risk of counting events twice when the trial is providing time-to-event data. Third, we included an analysis of hazard ratios where these data were available, which is the most appropriate analysis for time-to-event data.[27]

Limitations

We could only report the available data. Subgroup analyses based on factors such as location of MI, diabetes mellitus, left ventricular function, location, and complexity of residual CAD was not possible because trials did not uniformly report these data, and if they did, it was only for the primary outcome measure, which differed across each trial. The individual trials also had other differences in methodology and reporting, but this problem is common to all meta-analyses. It would benefit clinical trialists to attempt to harmonize their definitions of events and their outcome measures to facilitate more accurate synthesis of their results.

The majority of trials did not routinely report post-procedure elevations in cardiac enzymes, so it was not possible to analyze them. The DANAMI trial reported 2 periprocedural MIs in the complete revascularization group but without any details on enzyme elevations; the trial by Dambrink et al[23] reported 4 periprocedural MIs in the complete revascularization group.

Sicker, higher risk patients were generally excluded from these trials. Consequently, our results cannot be extrapolated to patients with cardiogenic shock or those with left main CAD or chronic total occlusions.

Time-to-event data are best analyzed using hazard ratios or survival plots. When we performed this analysis, the benefit of complete revascularization remained for MI and revascularization but was not statistically significant for cardiac death. This is likely due to the reduced sample size because not all trials provided hazard ratios or survival plots. If hazard ratios were

available for all included studies, the primary end point may have reached statistical significance using hazard ratios, but these data were not available.

CONCLUSIONS

For patients with STEMI and multivessel disease, complete revascularization with PCI significantly improves hard clinical outcomes including cardiovascular death and MI. These data have implications for clinical practice guidelines regarding recommendations for complete revascularization following STEMI.

ARTICLE INFORMATION

Received November 11, 2019; accepted May 4, 2020.

Affiliations

From the Columbia University Medical Center/New York-Presbyterian Hospital, New York, NY (Y.A., M.P., Z.A., M.A.P., J.W.M., M.B.L., D.K.); National Heart and Lung Institute, Imperial College London, London, United Kingdom (Y.A., J.P.H., A.A., H.S., C.M.C., T.W., M.S.-S., R.A.-L., S.S., D.F.); Cardiovascular Research Foundation, New York, NY (G.W.S.); The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (G.W.S.).

Sources of Funding

None.

Disclosures

Dr Cook and Dr Al-Lamee have conducted teaching sessions supported by Volcano Corp. Dr Sen has attended and conducted teaching sessions supported by Volcano Corp, St Jude Medical, Medtronic, Pfizer, and AstraZeneca; has received research grant support from Philips, AstraZeneca, Medtronic, and Pfizer; and has received speaking honoraria from Pfizer and Volcano-Philips. Manish A. Parikh: Speakers bureau—Medtronic, Boston Scientific, Abbott Vascular, CSI; advisory board—Philips, Abbott Vascular, Medtronic. A. Kirtane: Institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical; personal: conference honoraria and travel/meal reimbursements only. Ziad A. Ali: institutional research grants to Columbia University from St. Jude Medical, and Cardiovascular Systems Inc. Consultant to St Jude Medical, ACIST. Dimitri Karmpaliotis: Speaker's bureau - Abbott Vascular, Boston Scientific, Medtronic; consultant - Vascular Solutions. The remaining authors have no disclosures to report.

Supplementary Materials

Data S1
Table S1
Figures S1–S64
References 9, 16–24

REFERENCES

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet*. 2003;361:13–20.
2. Rasoul S, Ottervanger JP, de Boer M-J, Dambrink J-HE, Hoorntje JCA, Marcel Gosselink AT, Zijlstra F, Suryapranata H, van 't Hof AWJ; Zwolle Myocardial Infarction Study Group. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction. *Coron Artery Dis*. 2009;20:415–421.
3. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, Lansky AJ, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. *Eur Heart J*. 2007;28:1709–1716.
4. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J*. 2014;35:2541–2619.
5. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;127:e362–e425.
6. Ahmad Y, Cook C, Shun-Shin M, Balu A, Keene D, Nijjer S, Petraco R, Baker CS, Malik IS, Bellamy MF, et al. Resolving the paradox of randomised controlled trials and observational studies comparing multivessel angioplasty and culprit only angioplasty at the time of STEMI. *Int J Cardiol*. 2016;222:1–8.
7. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al.; ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2018;39:119–177.
8. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. *Circulation*. 2016;133:1135–1147.
9. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, Meeks B, Di Pasquale G, López-Sendón J, Faxon DP, et al. Complete revascularization with multivessel PCI for myocardial infarction. *N Engl J Med*. 2019;381:1411–1421.
10. Gershlick AH, Banning AS, Parker E, Wang D, Budgeon CA, Kelly DJ, Kane PO, Dalby M, Hetherington SL, McCann GP, et al. Long-term follow-up of complete versus lesion-only revascularization in STEMI and multivessel disease: the CvLPRIT Trial. *J Am Coll Cardiol*. 2019;74:3083–3094.
11. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151:264–269.
12. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC; Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
13. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019)*. Cochrane, 2019. Available at: www.training.cochrane.org/handbook.
14. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21:1539–1558.
15. R Core Team. *R: A Language and Environment for Statistical Computing [Internet]*. Vienna, Austria: R Foundation for Statistical Computing; 2016. Available at: https://www.R-project.org/. Accessed January 1, 2019.
16. Viechtbauer, W. Conducting meta-analyses in R with the metafor package. *Journal of Statistical Software*. 2010;36:1–48. DOI: http://dx.doi.org/10.18637/jss.v036.i03.
17. Smits PC, Abdel-Wahab M, Neumann F-J, Boxma-de Klerk BM, Lunde K, Schotborgh CE, Piroth Z, Horak D, Wlodarczak A, Ong PJ, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. *N Engl J Med*. 2017;376:1234–1244.
18. Hamza M, Mahmoud AN, Elgendy IY. A randomized trial of complete versus culprit-only revascularization during primary percutaneous coronary intervention in diabetic patients with acute ST elevation myocardial infarction and multi vessel disease: complete versus culprit revascularization in STEMI diabetic patients. *J Interv Cardiol*. 2016;29:241–247.
19. Zhang J, Wang Q, Yang H, Ma L, Fu X, Hou W, Feng J, Liu X. [Evaluation of different revascularization strategies for patients with acute myocardial infarction with lesions of multiple coronary arteries after primary

percutaneous coronary intervention and its economic evaluation]. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*. 2015;27:169–174.
20. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Clemmensen P, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. *Lancet*. 2015;386:665–671.
21. Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease. *J Am Coll Cardiol*. 2015;65:963–972.
22. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Oldroyd KG. Randomized trial of preventive angioplasty in myocardial infarction. *N Engl J Med*. 2013;369:1115–1123.
23. Dambrink J-H, Debrauwere J, van 't Hof A, Ottervanger J-P, Gosselink AT, Hoorntje J, de Boer M-J, Suryapranata H. Non-culprit lesions detected during primary PCI: treat invasively or follow the guidelines? *EuroIntervention*. 2010;5:968–975.
24. Politi L, Sgura F, Rossi R, Monopoli D, Guerri E, Leuzzi C, Bursi F, Sangiorgi GM, Modena MG. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. *Heart*. 2010;96:662–667.
25. Di Mario C, Mara S, Flavio A, Imad S, Antonio M, Anna P, Emanuela P, Stefano DS, Angelo R, Stefania C, et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat™ for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. *Int J Cardiovasc Intervent*. 2004;6:128–133.
26. Wood DA, Cairns JA, Wang J, Mehran R, Storey RF, Nguyen H, Meeks B, Kunadian V, Tanguay JF, Kim HH, et al. Timing of staged nonculprit artery revascularization in patients with ST-segment elevation myocardial infarction: COMPLETE trial. *J Am Coll Cardiol*. 2019;74:2713–2723.
27. Ahmad Y, Howard JP, Arnold A, Shin MS, Cook C, Petraco R, Demir O, Williams L, Iglesias JF, Sutaria N, et al. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. *Eur Heart J*. 2018;39:1638–1649.

SUPPLEMENTAL MATERIAL

Data S1.

Summary of use of stent types in included trials:

In the COMPLETE trial, 86.4% of patients in the complete revascularization arm and 86.1% of the culprit-only arm received a drug-eluting stent during the index procedure. A breakdown of different drug-eluting stent types was not provided.

In the COMPARE-ACUTE trial, 95.4% in the complete revascuarization arm received a DES, and in the culprit-only arm 96.1% received DES. In the complete arm, this was broken down to 227 Xience (72.8%), 6 Promus (1.9%), 79 Other DES (25.3%); and in the culprit arm this was broken down to 442 Xience (71.3%), 20 Promus (3.2%), 158 Other DES (25.5%).

In the CvLPRIT trial, 95.9% of patients in the complete revascularization arm and 90.7% of the culprit-only arm received a drug-eluting stent. A breakdown of different drug-eluting stent types was not provided.

In the DAMBRINK trial, 22.5% in the complete revascularization arm and 17.1% in the culprit-only arm received a drug-eluting stent.

In the DANAMI trial, 93% in the complete revascularization arm and 95% in culprit-only arm received a drug-eluting stent.

In the Hamza trial, drug-eluting stents were used in all patients.

In the HELP-AMI trial, the heparin-coated Bx velocity stents were used in all patients.

In the Politi trial, 16.9% in the complete revascularization arm and 11.9% in culprit-only arm received a drug-eluting stent.

In the PRAMI trial, 63% in the complete revascularization arm and 58% in the culprit-only arm received a drug-eluting stent.

Table S1. Endpoint definitions.

Author	Study Acronym	Definition of CV Death	Definition of MI	Definition of IDR
Mehta *et al*[9]	COMPLETE	Clear CV or unknown cause of death. Documented non-CV deaths classified as non-CV (e.g. cancer)	Abnormal troponin + one of new symptoms, new ST-T change / LBBB / Q waves, new RWMA / non-viable myocardium on imaging or autopsy/angiographic intra-coronary/stent thrombus. Cardiac death with symptoms and ST-T change / LBBB but death prior to troponin measurement. Peri-PCI MI: troponin >35x ULN / CK-MB >5x ULN + one of new symptoms, new ST-T change / LBBB, new RWMA / non-viable myocardium on imaging or evidence of PCI complication. Peri-CABG: troponin >70x ULN / CK-MB >10x ULN + one of new q waves / LBBB, new graft/native vessel occlusion or new RWMA / non-viable myocardium on imaging.	All of the following: 1) CCS class ≥2 angina despite GDMT, 2) PCI / CABG of culprit lesion (within 5mm of stented segment) or non-culprit elsion that resulted in trial eligibility, 3) one of: positive functional study demonstrating reversible ischaemia, new ischaemic ECG changes consistent with a coronary territory or FFR ≤ 0.8.
Smits *et al.*[16]	Compare-Acute	CV death not reported	Rise and fall of troponin / CK-MB + one of symptoms, q waves, ST elevation / depression. Q waves without CK-MB rise. Confirmed MI without Q waves. Peri-PCI MI: rise of CK-MB >3x ULN within 48 hours. Peri-CABG PCI: rise of CK-MB >5x ULN within 7 days. If peak CK/CK-MB from index infarct not reached: chest pain >20 minutes, or new ecg changes, with peak CK/CK-MB 24 hours later ≥50% higher. If CK/CK-MB falling or normalised within 24 hours of index PCI: new rise >2x ULN if normalised or >50% nadir if falling.	Any revascularisation (not IDR)
Hamza *et a*[17]	n/a	CV death not reported.	Not stated	Not stated
Zhang *et al*[18]	n/a	Not translated	Not translated	Revascularisation not reported.
Engstrøm *et al.*[19]	DANAMI-3-PRIMULTI	Not stated	Not stated	ischaemia-driven (subjective or objective) revascularisation of lesions in non-infarct related arteries

Gerschlick *et al*.[20]	CvLPRIT	Any cardiac causes, or other vascular causes (e.g. pulmonary embolism, aortic dissection)	Type 1: Spontaneous re-MI: Recurrent angina symptoms or new ECG changes occurring before PCI or <48 hours from PCI compatible with re-MI with an elevation of CK-MB, troponin, or total CK above ULN and 20% higher than previous value. Type 4a: CK-MB or total CK >3 times the ULN within 48 hours following PCI. If the pre-PCI CK-MB or total CK level > ULN, also: either falling CK-MB or total CK level prior to the onset of the suspected event, or a peak of biomarker ≥ 20% above the previous value. With appropriate clinical presentation or new ischemic ECG changes (ST elevation/depression or new Q waves/LBBB). Type 4b: MI associated with stent thrombosis on angiography/autopsy as well as fulfilling the criteria of spontaneous MI (Type 1)	Target lesion re-interventions: inside or within 5 mm of stent. Target vessel revascularisation: repeated interventions in the same vessel by PCI/CABG. PCI to lesions not identified previously. CABG for new symptoms or complications of PCI.
Wald *et al*.[21]	PRAMI	Not stated	Symptoms of cardiac ischemia and a troponin > ULN. For patients with a recurrent MI within 14 days after randomization, the definition required new ST change or LBBB with angiographic evidence of coronary- artery occlusion	Repeat revascularisation was a secondary outcome (not IDR).
Dambrink *et al*.[22]	n/a	Not reported	New Q-waves or a new CK and CK-MB rise > ULN (including peri-procedural MI)	Additional unplanned revascularisations reported (not IDR)
Politi *et al*.[23]	n/a	Not stated	Not stated	Not stated
Di Mario *et al*.[24]	HELP AMI	Not stated	Not Stated	Not Stated

CV – cardiovascular, MI – myocardial infarction, RWMA – regional wall motion abnormality, LBBB – left bundle branch block, IDR – ischaemia driven revascularisation, PCI – percutaneous catheter intervention, CABG – Coronary Artery Bypass Grafting, CCS – Canadian Cardiovascular Society, GDMT – guideline directed medical therapy

Figure S1. Funnel plot for publication bias.



Figure S2. Effect of complete revascularization on risk of spontaneous myocardial infarction.



Figure S3. Effect of complete revascularization on risk of contrast-induced nephropathy.



Figure S4. Effect of timing of complete revascularization on myocardial infarction.



Figure S5. Effect of timing of complete revascularization on unplanned revascularization.



Figure S6. Effect of FFR-guided revascularization on cardiovascular death.



Figure S7. Effect of FFR-guided revascularization on all-cause mortality.



Figure S8. Effect of FFR-guided revascularization on myocardial infarction.



Figure S9. Effect of FFR-guided revascularization on unplanned revascularization.



Figure S10. Freedom from cardiovascular death.



Figure S11. Freedom from myocardial infarction.



Figure S12. Freedom from all-cause death.



Figure S13. Freedom from unplanned revascularization.



Figure S14. Fixed effects analysis for effect of complete revascularization on risk of cardiovascular death.



Figure S15. Fixed effects analysis for effect of complete revascularization on risk of myocardial infarction.



Figure S16. Fixed effects analysis for effect of complete revascularization on risk of all-cause mortality.



Figure S17. Fixed effects analysis for effect of complete revascularization on risk of unplanned revascularization.



Figure S18. Fixed effects analysis for effect of complete revascularization on risk of major bleeding.



Figure S19. Sensitivity analysis for risk of cardiovascular death including only trials at low-risk of bias.



Figure S20. Sensitivity analysis for risk of myocardial infarction including only trials at low-risk of bias.



Figure S21. Sensitivity analysis for risk of all-cause mortality including only trials at low-risk of bias.



Figure S22. Sensitivity analysis for risk of unplanned revascularization including only trials at low-risk of bias.



Figure S23. Sensitivity analysis excluding trials with low use of drug-eluting stents for the effect of complete revascularization on risk of cardiovascular death.



Figure S24. Sensitivity analysis excluding trials with low use of drug-eluting stents for the effect of complete revascularization on risk of myocardial infarction.



Figure S25. Sensitivity analysis excluding trials with low use of drug-eluting stents for the effect of complete revascularization on risk of all-cause mortality.



Figure S26. Sensitivity analysis excluding trials with low use of drug-eluting stents for the effect of complete revascularization on risk of unplanned revascularization.



Figure S27. Sensitivity analysis excluding trials with low use of drug-eluting stents for the effect of complete revascularization on risk of major bleeding.



Figure S28. Sensitivity analysis for risk of cardiovascular death excluding the COMPARE ACUTE trial.



Figure S29. Sensitivity analysis for risk of cardiovascular death excluding the COMPLETE trial.



Figure S30. Sensitivity analysis for risk of cardiovascular death excluding the CVLPRIT trial



Figure S31. Sensitivity analysis for risk of cardiovascular death excluding the DANAMI 3 trial



Figure S32. Sensitivity analysis for risk of cardiovascular death excluding the Politi trial



Figure S33. Sensitivity analysis for risk of cardiovascular death excluding the PRAMI trial



Figure S34. Sensitivity analysis for risk of cardiovascular death excluding the Zhang trial



Figure S35. Sensitivity analysis for risk of myocardial infarction excluding the COMPARE ACUTE trial



Figure 36. Sensitivity analysis for risk of myocardial infarction excluding the COMPLETE trial



Figure S37. Sensitivity analysis for risk of myocardial infarction excluding the CvLPRIT trial



Figure S38. Sensitivity analysis for risk of myocardial infarction excluding the Dambrink trial



Figure S39. Sensitivity analysis for risk of myocardial infarction excluding the DANAMI 3 trial



Figure S40. Sensitivity analysis for risk of myocardial infarction excluding the Hamza trial



Figure S41. Sensitivity analysis for risk of myocardial infarction excluding the HELP-AMI trial



Figure S42. Sensitivity analysis for risk of myocardial infarction excluding the Politi trial



Figure S43. Sensitivity analysis for risk of myocardial infarction excluding the PRAMI trial



Figure S44. Sensitivity analysis for risk of myocardial infarction excluding the Zhang trial



Figure S45. Sensitivity analysis for risk of all-cause mortality excluding the COMPARE ACUTE trial



Figure S46. Sensitivity analysis for risk of all-cause mortality excluding the COMPLETE trial



Figure S47. Sensitivity analysis for risk of all-cause mortality excluding the CvLPRIT trial



Figure S48. Sensitivity analysis for risk of all-cause mortality excluding the Dambrink trial



Figure S49. Sensitivity analysis for risk of all-cause mortality excluding the DANAMI 3 trial



Figure S50. Sensitivity analysis for risk of all-cause mortality excluding the Hamza trial



Figure S51. Sensitivity analysis for risk of all-cause mortality excluding the HELP-AMI trial



Figure S52. Sensitivity analysis for risk of all-cause mortality excluding the Politi trial



Figure S53. Sensitivity analysis for risk of all-cause mortality excluding the PRAMI trial



Figure S54. Sensitivity analysis for risk of all-cause mortality excluding the Zhang trial



Figure S55. Sensitivity analysis for risk of unplanned revascularization excluding the COMPARE ACUTE trial



Figure S56. Sensitivity analysis for risk of unplanned revascularization excluding the COMPLETE trial



Figure S57. Sensitivity analysis for risk of unplanned revascularization excluding the CvLPRIT trial



Figure S58. Sensitivity analysis for risk of unplanned revascularization excluding the Dambrink trial



Figure S59. Sensitivity analysis for risk of unplanned revascularization excluding the DANAMI 3 trial



Figure S60. Sensitivity analysis for risk of unplanned revascularization excluding the Hamza trial



Figure S61. Sensitivity analysis for risk of unplanned revascularization excluding the HELP-AMI trial



Figure S62. Sensitivity analysis for risk of unplanned revascularization excluding the Politi trial



Figure S63. Sensitivity analysis for risk of unplanned revascularization excluding the PRAMI trial



Figure S64. Sensitivity analysis for risk of unplanned revascularization excluding the Zhang trial